UNIVERSITY of York

This is a repository copy of Joining the Dots:Linking Disconnected Networks of Evidence Using Dose-Response, Model-Based Network Meta-analysis (MBNMA).

White Rose Research Online URL for this paper: <u>https://eprints.whiterose.ac.uk/168878/</u>

Version: Accepted Version

Article:

Pedder, Hugo, Dias, Sofia orcid.org/0000-0002-2172-0221, Bennetts, Meg et al. (2 more authors) (2021) Joining the Dots:Linking Disconnected Networks of Evidence Using Dose-Response, Model-Based Network Meta-analysis (MBNMA). Medical Decision Making. pp. 194-208. ISSN 1552-681X

https://doi.org/10.1177/0272989X20983315

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/

Joining the Dots – Linking disconnected networks of evidence using dose-response Model-Based Network Meta-Analysis

Authors: Pedder Hugo¹, Dias Sofia², Bennetts Meg³, Boucher Martin³, Welton Nicky J.¹ **Journal:** Medical Decision Making

¹Dept Population Health Sciences, Bristol Medical School, University of Bristol, BS8 2PS, UK

²Centre for Reviews and Dissemination, University of York, UK

³Pharmacometrics, Pfizer Ltd, Sandwich, Kent, UK

Word count: 4964

Financial support for NJW, SD, and HP was provided in part by a grant from the MRC Methodology Research Programme (ref MR/M005615/1). NJW was partly supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The funding agreement ensured the authors' independence in designing the study, interpreting the data, writing, and publishing the report. The following authors are employed by Pfizer Ltd: MB and MB. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

Abstract

Introduction: Network meta-analysis (NMA) synthesises direct and indirect evidence on multiple treatments to estimate their relative effectiveness. However, comparisons between disconnected treatments are not possible without making strong assumptions. When studies including multiple doses of the same drug are available, model-based NMA (MBNMA) presents a novel solution to this problem by modelling a parametric dose-response relationship within a NMA framework. In this paper, we illustrate several scenarios in which dose-response MBNMA can connect and strengthen evidence networks.

Methods: We created illustrative datasets by removing studies or treatments from a NMA of triptans for migraine relief. We fitted MBNMA models with different dose-response relationships. For connected networks, we compared MBNMA estimates with NMA estimates. For disconnected networks, we compared MBNMA estimates with NMA estimates from an "augmented" network connected by adding studies or treatments back into the dataset.

Results: In connected networks relative effect estimates from MBNMA were more precise than those from NMA models (ratio of posterior SDs NMAvsMBNMA: median=1.13; range=1.04-1.68). In disconnected networks MBNMA provided estimates for all treatments where NMA could not and were consistent with NMA estimates from augmented networks for 15/18 datasets. In the remaining 3/18 datasets a more complex dose-response relationship was required than could be fitted with the available evidence.

Conclusions: Where information on multiple doses is available, MBNMA can connect disconnected networks and increase precision, whilst making less strong assumptions than alternative approaches. MBNMA relies on correct specification of the dose-response relationship which requires sufficient data at different doses to allow reliable estimation. We recommend that systematic reviews for NMA search for and include evidence (including phase-II trials) on multiple doses of agents where available.

Introduction

Healthcare policy decisions increasingly use cost-effectiveness analysis to support decision-making by healthcare professionals, a key element of which involves estimating the relative clinical effectiveness of multiple treatment options. This is typically done using network meta-analysis (NMA) which pools the results of randomised-controlled trials (RCTs) enabling comparison of multiple treatments simultaneously, provided they form a connected network of treatment comparisons^{1,2}. A connected network is one in which there is a path of RCT comparisons that can be followed between any pair of treatments in the network. For example, Figure 1a illustrates a connected network, whereas Figure 1b illustrates a network where treatments A and X are not connected to treatments B and Y. It is not possible to obtain a relative effect estimate for pairs of treatments that are not connected, for example B vs A in the network in Figure 1b, using standard NMA methods.

In health technology assessment (HTA) it is common for networks of evidence to be disconnected or weakly connected, so that relative effects are either not estimable or very imprecisely estimated. This is in part due to new drugs obtaining marketing authorisation before mature phase-III RCT evidence has become available; partly due to different comparator treatments being needed for marketing approval than by reimbursement agencies; and also due to drugs being marketed in precisely defined patient populations, limiting the available evidence on comparator treatments^{3,4}.

Various methods have been proposed to deal with disconnected networks in NMA⁵. These include using observational or registry data⁶, evidence in other populations⁷, expert opinion⁸⁻¹⁰, population adjustment methods^{11,12,13} hierarchical models¹⁴, and modelling intervention components^{15,16} to connect networks. For example in a HTA comparing treatments for plaque psoriasis in children and young people⁷, adalimumab was disconnected from the network and evidence from an adult trial was used to enable a NMA comparing the treatments of interest. In another HTA on follicular lymphoma, different therapies with or without rituximab were compared, resulting in no common comparators¹⁷, however by assuming the effects of the components in the combination therapies to be additive (with no interactions), the effects of the therapy given in both arms "cancels out", so that each trial provides information on rituximab as an adjunct vs no adjunct, and the network connects.

A third example is an HTA for relapsed and refractory multiple myeloma¹⁸, where there was no RCT evidence connecting pomalidomide with comparators panobinostat or bendomustine. Analysis of individual patient data (IPD) from single arms and population adjustment methods were used to connect the network. All of these methods however make strong and typically untestable assumptions.

Model-Based Network Meta-Analysis (MBNMA) is a new methodology that has the potential to connect networks of evidence in situations where there is evidence on multiple doses of one or more agents, or observations at multiple follow-up times, by combining parametric models of dose-response¹⁹ or time-course²⁰ with NMA in a statistically robust way that preserves randomisation in included RCTs. One advantage of this approach is that it allows inclusion of trials from earlier phases of drug development into the network so that evidence on agents at unlicensed doses, or evidence at a variety of time-points can be used to strengthen the evidence on the licensed treatments and time-points that are of interest. For example, in the plaque psoriasis example⁷, phase-II dose-response information may be available on children for each treatment, which could connect the network without needing to rely on evidence in a different population (adults). Similarly, for the multiple myeloma example¹⁸, there was evidence on multiple doses of bendamustine which could potentially connect the network. Subsequent appraisals of newer drugs for multiple myeloma have compared multiple doses²¹.

Figures 1c and 1d illustrate two scenarios where there are studies of A_1vsX and B_1vsY (where treatments are defined by agent, A, B, X, Y, with subscript indicating dose, where dose=1 is the licensed dose). A_1 and B_1 are disconnected, but there is evidence for a range of doses for at least one of the agents. In Figure 1c, by explicitly modelling the dose-response relationship using MBNMA, a placebo response (i.e. at dose=0, where $A_0=B_0$) is estimated for both agents (even agent A where placebo has not been included in any trial). This connects the network and a relative effect estimate between A_1 and B_1 can be obtained. In Figure 1d, A_1 is only connected to B at a sub-optimal dose and is not connected to placebo. However, by using MBNMA to model the dose-response relationship, $B_{0.5}$ can be connected to other doses of B by interpolation, thus connecting the network and allowing for a comparison of A_1 versus B_1 .

In this paper, we aim to illustrate the potential of dose-response MBNMA to connect and strengthen evidence networks in a range of different scenarios. We begin by describing the MBNMA method¹⁹. We then introduce a network of triptans for migraine relief and describe how we manipulate this dataset to obtain a set of scenario networks with different features with which to illustrate the performance of the MBNMA method. We then present and compare results from MBNMA and NMA of the scenarios and end with a discussion.

Methods

We firstly describe standard NMA, the extension to dose-response MBNMA, and then describe how we generated a range of scenarios from the triptans datasets on which the methods are illustrated.

Network Meta-Analysis

Following the methods of Lu and Ades¹ we define NMA as follows. For each study *i* the aggregated data for arm *k* provides information on some parameter $\theta_{i,k}$ (e.g. probability, mean outcome) which is modelled using a generalised linear model²²:

$$g(\theta_{i,k}) = \begin{cases} \mu_i & \text{when } k = 1\\ \mu_i + \delta_{i,k} & \text{when } k \ge 2 \end{cases}$$
[1]

where g is a link function that transforms the outcome onto an appropriate scale (e.g. a logistic function for binary outcomes, or an identity function for continuous outcomes), μ_i is the control arm (reference) treatment of study *i*, which is modelled as a nuisance parameter and given a vague prior, and $\delta_{i,k}$ is the study-specific treatment relative treatment effect for the treatment used in arm *k* relative to the reference treatment in arm 1 of study *i*. In a random effects model these are assumed to be normally distributed around a mean treatment effect that adheres to consistency relationships, with between-study variance τ^2 that is common across treatment comparisons:

$$\delta_{i,k} \sim N(d_{t_{i,k}} - d_{t_{i,1}}, \tau^2)$$
[2]

where $d_{t_{i,k}}$ is the mean treatment effect of treatment $t_{i,k}$ compared to the network reference treatment. The consistency relationships reflect the comparison made between the treatment $t_{i,k}$ used on arm k and the treatment $t_{i,1}$ used on arm 1 of each study. A common effects model that assumes no between-study heterogeneity can be obtained by setting $\tau^2 = 0$.

Dose-Response Model-Based Network Meta-Analysis

The dose-response MBNMA model extends the standard NMA model to incorporate a dose-response relationship¹⁹.

We define a treatment in arm k of study i as a specific dose, $x_{i,k}$, of a specific agent, $a_{i,k}$. The model is exactly as for the NMA equation [1] above, but equation [2] is replaced with

$$\delta_{i,k} \sim N(f(x_{i,k}, a_{i,k}) - f(x_{i,1}, a_{i,1}), \tau^2)$$
[3]

where $f(x_{i,k}, a_{i,k})$ is a dose-response function for dose $x_{i,k}$, agent $a_{i,k}$, and τ^2 is the between-study heterogeneity (set to zero for a common effects model). Multi-arm trials are dealt with in the same way as in standard NMA².

Any dose-response function could be fitted, although this will be limited by the number of doses of an agent included in RCTs in the network. For example, for an exponential model:

$$f(x_{i,k}, a_{i,k}) = E_{0,i} + \beta_{a_{i,k}} (1 - e^{-x_{i,k}})$$

where $E_{0,i}$ is the placebo response at $x_{i,k} = 0$ in study *i*, and $\beta_{a_{i,k}}$ is the rate parameter for the agent in arm *k* of study *i*. The consistency equation in equation [3] means that the $E_{0,i}$ terms cancel out when forming the relative effects, so $E_{0,i}$ is not explicitly estimated within the model. In the exponential model there is a single dose-response parameter to be estimated for each agent, meaning that studies with at least two doses (one of which could be placebo) of each agent are required to estimate β_a .

Another commonly used dose-response model is the Emax function²³, which estimates the maximum response relative to placebo ($E_{\max,a}$) and the dose at which half the maximum response can be achieved ($ED_{50.a}$):

$$f(x_{i,k}, a_{i,k}) = E_{0,i} + \frac{E_{\max,a_{i,k}} x_{i,k}}{E D_{50,a_{i,k}} + x_{i,k}}$$
[4]

Again we do not explicitly estimate $E_{0,i}$, as these terms cancel out when equation [4] is inserted into equation [3]. The $E_{\max,a}$ and $ED_{50,a}$ parameters may be correlated, and this correlation can be estimated by specifying a bivariate normal distribution with a Wishart prior on the covariance matrix (see Analyses and Implementation section and equation [5]). This extends to models with more than two parameters where a multivariate normal distribution can be specified.

In order to estimate both parameters of the Emax function, studies with at least three doses of a specific agent are required.

Example datasets

A dataset of published RCTs for the efficacy of triptans in migraine relief²⁴ was used to illustrate the analyses. The outcome measured was the proportion of patients who were headache-free at two hours. This dataset contains 22 treatments, 7 agents and placebo, investigated in 70 studies. Doses are standardised to multiples of each agent's "common" dose²⁴.

From this complete dataset we generated manipulated datasets by removing specific treatments and studies to represent several scenarios that might be found in practice in order to compare the performance of NMA and MBNMA methods. If only a single arm remained in a study after excluding treatments then that study was excluded. Complete and manipulated datasets generated for all scenarios can be found in Supplementary Materials.

Scenario 1 - Connected network

In scenario 1, datasets illustrate the use of MBNMA in connected networks with different amounts of dose-response information. Comparisons of interest are at the common dose (dose = 1).

Scenario 1A

Scenario 1A is a manipulated dataset composed of only a single common dose of each agent and placebo in the triptans dataset (Figure 2A), which left 59 studies, 7 treatments (all common doses of different agents) and placebo. This scenario may be similar to datasets found in HTAs or clinical guidelines, where only comparisons between licensed doses of each agent are of interest and included in the evidence network.

Scenario 1B

Scenario 1B is the complete triptans dataset including all doses and agents. This includes 70 studies, investigating 22 treatments, 7 agents and placebo (Figure 2B).

Scenarios 2 and 3 – Disconnected networks

For simplicity, we suppose the objective is to compare two treatments of interest (agents of interest at the common dose). We take each pair of agents in turn and remove evidence on all other agents from the network, leaving only different doses of each agent of interest. These datasets are then manipulated further to obtain disconnected networks for scenarios 2 and 3 (see below). Manipulating the original dataset in this way provides us with a number of different, simpler datasets which can be used to examine how the reliability of MBNMA changes depending on the agents and doses included.

We follow the approach taken by Beliveau et al.²⁵ to compare MBNMA models fitted to disconnected networks with NMA models fitted to connected networks. We first fit MBNMA models to

disconnected networks and calculated relative effects for the treatment comparison of interest in the network. Then we added in data to connect the networks, generating "augmented" datasets on which it was possible to fit NMA models. The relative effects calculated between the two sets of data were compared to assess the level of agreement.

Scenario 2 – *Disconnected due to absence of common comparator (e.g. placebo)*

This illustrates a situation in which there is evidence on different doses for an agent of interest (e.g. from early-phase drug development trials), but there is no common comparator (Figure 1c).

To explore this, we generated a disconnected dataset by removing all placebo arms from the datasets for each pair of agents (having already removed agents not of interest). For each of these networks, we also constructed an "augmented" dataset by including comparisons between any doses of the included agents versus placebo so that the networks were fully connected and both MBNMA and NMA models could be fitted.

Scenario 3 – Disconnected due to comparison with a dose that has not been evaluated in other trials This illustrates a scenario shown in Figure 1d in which the treatment of interest (A₁) has only been investigated in a study comparing a non-licensed or non-optimal dose of a comparator (B_{0.5}) which is not connected to the dose of interest (B₁) via any pathway of head-to-head evidence. In practice, this non-licensed comparison might occur with a sub-optimal dose of a comparator, such as in the GALLIUM trial comparing obinutuzumab for untreated advanced follicular lymphoma to rituximab administered for a shorter series of doses²⁶.

Disconnected datasets were therefore generated such that studies comparing a common dose of one agent versus a non-optimal dose of another were not connected to studies comparing other doses. Augmented datasets were then generated which included comparisons between all doses of both agents, including the common dose, so that the networks were fully connected.

Analyses and Implementation

All models were implemented using the package MBNMAdose version 0.2.7²⁷ in R version 3.6.1 with a seed of 210489. Models were run until convergence was reached for all monitored parameters, as assessed by the Gelman-Rubin statistic²⁸ and visual inspection of the chains.

The effective number of parameters were estimated using the plug-in method²⁹ for NMAs and using the Kullback-Leibler divergence³⁰ for MBNMAs. Deviance Information Criterion (DIC) was used to compare models, defined as the sum of the effective number of parameters added to the residual deviance.

Each dataset was analysed where possible using standard NMA and dose-response MBNMA. For both NMA and MBNMA, common and random effects models were compared. For MBNMA a model selection strategy was used to determine a suitable model, in which first all models that were within 3 DIC points of the model with the lowest DIC were identified³¹. Of these models the simplest was preferred – models with common treatment effects were selected in preference to those with random treatment effects, and models with an exponential dose-response function were selected in preference to those with an Emax dose-response function.

This approach was used in order to allow selection of a dose-response function that could potentially explain as much heterogeneity as possible. Exponential and Emax were the only dose-response functions examined as there was a biological justification for their use over other possible functions (e.g. linear, quadratic)²³.

Vague normal prior distributions (N(0,1000)) were given to $d_{1,k}$, μ_i , $\beta_{a_{i,k}}$. For MBNMAs using the Emax function, a correlation was modelled between dose-response parameters by assigning them a multivariate normal prior:

$$\binom{E_{\max,a_{i,k}}}{\log(ED_{50,a_{i,k}})} \sim MVN(0,\Sigma)$$
^[5]

 $ED_{50,a_{i,k}}$ was modelled on the log-scale to ensure positive values. A minimally informative Wishart prior was used for $\Sigma^{-1} \sim Wishart(\begin{pmatrix} 1 & 0 \\ 0 & 1 \end{pmatrix}, 2)$. The between-study SD, τ , was given a half-normal prior distribution (N(0,400)). Unless otherwise stated, results are presented as posterior medians and 95% credible intervals (95%CrI)

Results

Scenario 1A

In the network involving only licenced doses of each agent and placebo, it was only possible to fit an MBNMA model with a single parameter (i.e. linear or exponential models). Based on the exponential MBNMA model relative effects estimated from selected NMA and MBNMA models were very similar (Figure 3). Between-study SD was reasonably high in both NMA (0.36; 95%CrI: 0.25, 0.50) and MBNMA (0.36; 95%CrI: 0.25, 0.50) models, and random effects models were selected in both instances. Model fit was similar for MBNMA and NMA models (Table 1). Due to the lack of dose-response information there was no gain in precision of the estimates in the MBNMA model compared with the NMA model.

Scenario 1B

In Scenario 1B, all available doses of each agent and placebo were included. Random effects models were selected for the NMA and MBNMA models. An Emax dose-response function was selected for the MBNMA model, with estimated correlation between Emax and ED50 dose-response parameters of 0.57 (95%CrI -0.53, 0.93) (Table 1).

The relative effects from both NMA and MBNMA were more precise for all agents at the common dose than in Scenario 1A due to inclusion of trials comparing non-licensed doses (Figure 4). Furthermore, MBNMA estimates were more precise than NMA estimates because of the additional information gained from modelling the dose-response relationship (Figure 4). The between-study SD was also slightly reduced for the MBNMA model (0.24; 95%CrI: 0.16, 0.34) compared with the NMA model (0.27; 95%CrI: 0.18, 0.38).

Scenario 2

It was possible to fit MBNMA models for 15 different agent vs agent comparisons generated in Scenario 2 (Supplementary Figure S1), but this was not possible for agent pairs including naratriptan since removing placebo arms left only single arms of studies including naratriptan.

In all disconnected datasets, an exponential dose-response MBNMA was selected with common treatment effects (Table 2). NMA models could not be estimated due to the networks being disconnected.

Relative effects estimated using MBNMA had high uncertainty (Figure 5), reflecting both the sparsity of data in the networks (number of data points per dataset: median = 22; range = 8 to 36) and the fact that no placebo evidence was available with which to inform the dose-response relationship at lower doses.

Augmenting the datasets by adding in placebo arms to connect the network enabled NMA models to be estimated. For MBNMA models an Emax dose-response function was selected for 12/15 datasets. Random treatment effects were selected over common effects in 12/15 datasets for both NMA and MBNMA models.

For most comparisons, results in the disconnected datasets were consistent with those in augmented datasets (Figure 5). However, for comparisons of almotriptan, rizatriptan and sumatriptan with eletriptan, estimates from the disconnected datasets were further away from the posterior medians of augmented dataset estimates, and results were less consistent.

Within augmented datasets, MBNMA estimates were very similar to corresponding NMA estimates, but with slightly increased precision leading to narrower 95% CrIs which were typically within those of the NMA estimates. The ratio of posterior SDs for the NMA estimates compared to the MBNMA estimates for each comparison had a median of 1.13 (range: 1.04 to 1.68).

Scenario 3

Given the constraints of the original triptans dataset, we were only able to generate suitable manipulated datasets for this scenario using higher doses of sumatriptan than the common dose. We were able to construct three networks to illustrate this scenario. Disconnected datasets therefore included a study comparing a common dose of one agent (either almotriptan/eletriptan/rizatriptan) versus twice the common dose of sumatriptan that is disconnected from studies comparing other doses of sumatriptan (including placebo) (Supplementary Figure S3). Augmented datasets were similar but included comparisons between the common dose of almotriptan/eletriptan/rizatriptan and all doses of sumatriptan so that the network is fully connected (Supplementary Figure S4).

For all datasets generated in Scenario 3, exponential MBNMA models with random treatment effects were selected (Table 3). NMA models could not be estimated due to the networks being disconnected. Precision was typically higher in relative effects for datasets generated in Scenario 3 than in Scenario 2, though it is unclear whether this was due to the specific inclusion of placebo within the dataset or due to the increased evidence available in Scenario 3 (Tables 2 and 3). When augmenting the datasets to enable estimation of NMA models, random effects models were selected in all datasets for both NMA and MBNMA models.

For all three comparisons, relative effects (either from MBNMA or NMA) in augmented datasets were entirely within the 95% CrIs of those estimated from MBNMAs in the disconnected datasets (Figure 6), suggesting that results were in agreement.

For augmented datasets, MBNMA estimates were very similar to NMA estimates. There was slightly increased precision in MBNMA estimates leading to narrower 95% CrIs. The ratios of posterior SDs for the NMA estimates compared to the corresponding MBNMA estimates for each comparison at the common dose were 1.03, 1.16 and 1.13 for almotriptan, eletriptan and rizatriptan respectively versus sumatriptan.

Discussion

This study illustrates several scenarios in which dose-response MBNMA can add value compared to standard NMA methods, either by improving precision or by connecting networks to enable comparisons between treatments of interest to be made. Connecting and strengthening networks is enabled by including additional evidence on non-optimal doses and via the modelling of a functional dose-response relationship, which can act as a link between disconnected treatments, either between different doses of the same agent along the dose-response curve, or between different agents via extrapolation of the placebo response.

Evidence on non-licensed doses is not typically included in HTA submissions, however such evidence will often exist and, if included using MBNMA, could add value by increasing precision even in connected networks. HTAs where multiple doses are of interest could also benefit from modelling using MBNMA. Examples include treatments for moderate-to-severe plaque psoriasis³²⁻³⁴ and retigabine for the adjunctive treatment of partial onset seizures in epilepsy³⁵.

In scenarios where the networks were disconnected (Scenarios 2 and 3), we found that MBNMA allowed estimation of relative effects which were consistent with NMA estimates obtained in augmented datasets where connections were added back into the network.

In the situation where dose-response information is available on two agents, but there is no direct comparison connecting the agents (Scenario 2), we found that, although MBNMA models could be estimated, there was limited information with which to estimate a complex dose-response function because of the comparatively few different doses of each agent in the triptans dataset, particularly at lower doses, when there is no placebo information. This was more problematic for eletriptan, as the dose-response relationship was better described by an Emax than an exponential function, which resulted in relative effects that were typically lower compared to those estimated from augmented datasets for eletriptan versus most other agents. Although phase-II studies would typically include a placebo arm, these studies may not be published, so a manufacturer may have placebo evidence for their own agent, but not necessarily for their competitors'.

In the situation where there was a direct comparison of the agents of interest, but the network was disconnected due to one of the agents being trialled at a non-optimal dose (Scenario 3), MBNMA was able to link agents at the optimal dose. Although there were only three possible combinations of agents in the triptans dataset for which it was possible to examine this scenario, estimates from augmented and disconnected datasets were in agreement. The reliability of the results from this scenario were due to considerable information at different doses for the agent connected via the dose-response relationship (sumatriptan in all three datasets). It is unclear how frequently these evidence structures might arise in HTAs as submissions typically only compare licensed doses.

Comparison with other methods for disconnected networks

Dose-response MBNMA has several advantages compared to other methods for linking disconnected networks provided sufficient data are available for estimation. In particular, the method only uses randomised evidence, and the statistical approach respects the randomisation in RCTs. This means that the estimates are unbiased provided there are no differences in treatment effect modifiers between studies (the standard assumption made in NMA) and the dose-response function is not mis-specified. The assumptions made regarding the dose-response relationship are also testable by evaluating the model's fit. Furthermore, MBNMA can be fitted using aggregate data only, without the need for IPD.

MBNMA is distinct from Model-Based Meta-Analysis (MBMA) which models dose-response but typically pools absolute rather than relative effects³⁶⁻³⁸. MBMA can be used with disconnected networks and allows inclusion of single-arm studies. However, it can produce biased estimates due to differences between studies in prognostic factors because it violates randomisation by ignoring within-study comparisons³⁹.

Another approach for dealing with disconnected networks is to fit a random effects model for the absolute effects on a specific reference treatment A. This random effects model is used to predict a treatment A effect in any study which is disconnected from the network, thus enabling that study to connect via treatment A¹⁴. This method does not require IPD and can incorporate single-arm studies. However, it can introduce important bias since it breaks randomisation by allowing within-study information to be influenced by information outside the study⁴⁰. It also relies on there being sufficient

studies which include treatment A to enable estimation of the random effects model. If there is substantial heterogeneity between studies, then the predicted A effect in disconnected studies will be imprecisely estimated, and network connections will be tenuous. The model also assumes that the baseline model has been correctly specified, which may require adjusting for study-level factors that affect the baseline response⁸. Beliveau et al.²⁵, applied random baseline effect NMA models to disconnected networks, finding that there was generally good overlap between random baseline models and standard NMA models in subsets of two different datasets. However, White et al.⁴⁰ show that bias would occur if underlying studies had different baseline predictors⁴⁰, and it is not clear how frequently this might be the case in practice. There is also no way of testing the assumption that the baseline effect has been correctly specified and important predictors may not be reported in included studies.

Population adjustment methods such as Matched Adjusted Indirect Comparisons^{11,12} or Simulated Treatment Comparisons¹³ have also been used to link disconnected treatments. These methods predict an absolute effect of a disconnected treatment Y in the population of a trial including treatment X, and the prediction is analysed as if it was an additional arm in the trial including X. However, the validity of comparisons relies on the assumption that the differences in absolute effects between studies can be fully explained by adjustment of prognostic variables (those that affect the outcome) as well as effect modifiers (those that alter the treatment effect)⁴¹. This is a very strong assumption that is impossible to test within the analysis, and it is unlikely that each trial has collected information on the same set of potential effect modifiers and prognostic factors. If this assumption does not hold then the resulting relative effects between disconnected treatments will be biased⁴¹. These methods also require IPD to be available for at least one RCT, though in HTA this is typically available for the manufacturer's trial.

An alternative method that makes use of functional assumptions regarding treatment definitions and can be performed using aggregate data is Component Network Meta-Analysis (CNMA)^{15,16}. This splits combinations of treatments into different "components", allowing for networks to be connected if treatments in separate subnetworks share at least one common component⁴² and has been used for this purpose in an analysis of cognitive behavioural therapies for panic disorder⁴³.

Whilst a network may be disconnected for a particular outcome, other correlated outcomes may be available, and a joint analysis using multivariate NMA may provide relative effect estimates between treatments that are disconnected for a given outcome, although correlations must be high to enable this⁴⁴. This approach was used to model the effects of first and second-line therapies for rheumatoid arthritis⁴⁵.

A more powerful approach is to model a structural relationship between multiple outcomes. Lu et al.⁴⁶ used piece-wise constant models to synthesise different networks (some of which were disconnected) at multiple follow-up times, and fractional polynomial models have also been used⁴⁷. Time-course MBNMA²⁰ provides a general framework to fit a functional time-course relationship, which can connect networks and provide considerably more precision than modelling the correlation alone²⁰. Time MBNMA could have potential benefit in HTAs, for example treatments for relapsing multiple sclerosis typically report at multiple time-points, but economic models are based on 6 months follow-up which is not reported for all treatments⁴⁸.

Assuming a common or exchangeable effect amongst similar treatments can be used as a way of connecting networks or dealing with sparse evidence structures^{49,50}, for example drugs in the same class with a similar mechanism of action, or biosimilar products. However, assuming a common effect is a very strong assumptions which can be difficult to justify, and assuming exchangeable effects will shrink treatment effects towards a class mean effect, which may not be realistic.

Other approaches that have been proposed to connect networks include incorporating non-randomised evidence⁶ or expert opinion⁸⁻¹⁰ to inform a prior distribution for the relative effect between the disconnected treatments. However, observational evidence is vulnerable to a range of biases which may invalidate relative effect estimates, and whilst expert opinion may be useful to put some bounds on plausible effect sizes, it is subjective and prone to bias.

Limitations

Although there are advantages of using dose-response MBNMA, there are also some clear limitations. The method is sensitive to misspecification of the dose-response function, and more complex dose-response models such as the Emax model require data on multiple doses of different agents to be able to estimate them. Doses that are more widely distributed will be more informative in identifying points of curvature in the dose-response function and are therefore likely to be important for mitigating bias⁵¹. This is highlighted by the lack of placebo data in Scenario 2, which generally resulted in underestimated relative effects for eletriptan versus other agents in disconnected datasets.

With only a single dose and placebo (or two doses without placebo) for each agent, only simple MBNMA models can be fitted, such as linear or exponential functions. Model fit statistics cannot help distinguish between models in this situation, although there may be some biological justification for an exponential function²³. External evidence may be helpful to support the choice of dose-response function, perhaps from data on related agents, or the same agents in different populations. Sharing either ED_{50} or E_{max} across agents within a class may make the Emax model easier to fit when data are limited, although this should only be done if there is clinical justification. Simulation studies to explore the performance of MBNMA models for different evidence structures would be a useful area for further work.

Conclusions

NMA relies on networks of treatments being connected. MBNMA allows re-connecting of networks via the dose-response relationship when evidence on multiple doses of agents is available. In our manipulated datasets MBNMA estimates were in agreement with those from NMA, had connecting studies been available. MBNMA makes fewer assumptions than other methods for linking disconnected networks, with the only additional assumption over NMA being that the dose-response relationship is correctly specified. This assumption can be tested by examining the fit of the model to the data, and/or based on the agent pharmacology. MBNMA can be performed using aggregate data and can add precision over NMA even in connected networks, when multiple doses are available.

MBNMA does however requires information on multiple doses for each agent, particularly to estimate more complex dose-response functions. We therefore recommend that systematic reviews supporting HTA should broaden their scope to include all doses in instances where use of dose-response MBNMA is expected to be of value. We also urge manufacturers to publish their phase-II study results, so that reimbursement decisions can make full use of the evidence available. Early phase evidence is taken into consideration when gaining regulatory approval, and incorporating this information into HTA may help bridge the evidence gap between regulators and reimbursement bodies^{3,4}.

References

- 1. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. *Stat Med.* 2004;23(20):3105-3124.
- 2. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. *Med Decis Making*. 2013;33(5):607-617.
- 3. Woolacott N, Corbett M, Jones-Diette J, Hodgson R. Methodological challenges for the evaluation of clinical effectiveness in the context of accelerated regulatory approval: an overview. *J Clin Epidemiol*. 2017;90:108-118.
- 4. Dickson R, Boland A, Duarte R, et al. EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties. *Appl Health Econ Health Policy*. 2018;16(4):429-432.
- 5. Stevens JW, Fletcher C, Downey G, Sutton A. A review of methods for comparing treatments evaluated in studies that form disconnected networks of evidence. *Res Synth Methods*. 2018;9(2):148-162.
- 6. Jenkins DA, Martina R, Dequen P, Bujkiewicz S, Abrams K. The Added Value of Real-World Evidence to Connect Disconnected Networks for Network Meta-Analysis: A Case Study in Rheumatoid Arthritis. *Value in Health.* 2016;19(7):A393.
- (NICE) National Institute for Health and Care Excellence. TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people. https://www.nice.org.uk/guidance/ta455. Published 2017. Accessed 27th February 2020.
- 8. Goring SM, Gustafson P, Liu Y, Saab S, Cline SK, Platt RW. Disconnected by design: analytic approach in treatment networks having no common comparator. *Res Synth Methods*. 2016;7(4):420-432.
- 9. Johnson SR, Tomlinson GA, Hawker GA, Granton JT, Feldman BM. Methods to elicit beliefs for Bayesian priors: a systematic review. *J Clin Epidemiol*. 2010;63(4):355-369.
- 10. Dias S, Welton NJ, Sutton AJ, Ades AE. Evidence synthesis for decision making 1: introduction. *Med Decis Making*. 2013;33(5):597-606.
- 11. Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. *Value Health.* 2012;15(6):940-947.
- 12. Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. *Pharmacoeconomics*. 2010;28(10):935-945.
- 13. Caro JJ, Ishak KJ. No Head-to-Head Trial? Simulate the Missing Arms. *Pharmacoeconomics*. 2010;28(10):957-967.
- 14. Thom HH, Capkun G, Cerulli A, Nixon RM, Howard LS. Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension. *BMC Med Res Methodol*. 2015;15:34.
- 15. Rucker G, Petropoulou M, Schwarzer G. Network meta-analysis of multicomponent interventions. *Biom J.* 2020;62(3):808-821.
- 16. Welton NJ, Caldwell DM, Adamopoulos E, Vedhara K. Mixed treatment comparison metaanalysis of complex interventions: psychological interventions in coronary heart disease. *Am J Epidemiol.* 2009;169(9):1158-1165.
- 17. (NICE) National Institute for Health and Care Excellence. TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma. <u>https://www.nice.org.uk/guidance/ta243</u>.
 Published 2012. Accessed 27th February 2020.
- 18. (NICE) National Institute for Health and Care Excellence. TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib. Published 2017. Accessed 13th May 2020.
- 19. Mawdsley D, Bennetts M, Dias S, Boucher M, Welton NJ. Model-Based Network Meta-Analysis: A Framework for Evidence Synthesis of Clinical Trial Data. *CPT Pharmacometrics Syst Pharmacol.* 2016;5(8):393-401.
- 20. Pedder H, Dias S, Bennetts M, Boucher M, Welton NJ. Modelling time-course relationships with multiple treatments: Model-based network meta-analysis for continuous summary outcomes. *Res Synth Methods*. 2019;10(2):267-286.

- 21. (NICE) National Institute for Health and Care Excellence. TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma. Published 2018. Accessed 13th May 2020.
- 22. Dias S, Ades AE, Welton NJ, Jansen JP, Sutton AJ. *Network meta-analysis for decision making*. Wiley; 2018.
- 23. Ette EI, Williams PJ. *Pharmacometrics: The science of quantitative pharmacology*. John Wiley & Sons; 2007.
- 24. Thorlund K, Mills EJ, Wu P, et al. Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis. *Cephalalgia*. 2014;34(4):258-267.
- 25. Beliveau A, Goring S, Platt RW, Gustafson P. Network meta-analysis of disconnected networks: How dangerous are random baseline treatment effects? *Res Synth Methods*. 2017;8(4):465-474.
- 26. (NICE) National Institute for Health and Care Excellence. TA513: Obinutuzumab for untreated advanced follicular lymphoma. <u>https://www.nice.org.uk/Guidance/TA513</u>. Published 2018. Accessed 28th February 2020.
- 27. *MBNMAdose: Run Dose-Response MBNMA Models. R package version 0.2.7.* [computer program]. CRAN; 2020.
- 28. Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. *Journal of Computational and Graphical Statistics*. 1998;7(4):434-455.
- 29. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model complexity and fit. *J R Statistic Soc B*. 2002;64(4):583-639.
- 30. Plummer M. Penalized loss functions for Bayesian model comparison. *Biostatistics*. 2008;9(3):523-539.
- 31. Lunn D, Jackson C, Best NG, Thomas A, Spiegelhalter DJ. *The BUGS Book: A Practical Introduction to Bayesian Analysis.* New York: Chapman and Hall/CRC; 2012.
- 32. (NICE) National Institute for Health and Care Excellence. TA511: Brodalumab for treating moderate to severe plaque psoriasis. <u>https://www.nice.org.uk/guidance/TA511</u>. Published 2018. Accessed 28th Februrary 2020.
- (NICE) National Institute for Health and Care Excellence. TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis. <u>https://www.nice.org.uk/guidance/ta574</u>. Published 2019. Accessed 28th February 2020.
- 34. (NICE) National Institute for Health and Care Excellence. TA442: Ixekizumab for treating moderate to severe plaque psoriasis. <u>https://www.nice.org.uk/guidance/ta442</u>. Published 2017. Accessed 28th February 2020.
- 35. Craig D, Rice S, Paton F, Fox D, Woolacott N. Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal. *Pharmacoeconomics*. 2013;31(2):101-110.
- 36. Thomas N, Sweeney K, Somayaji V. Meta-Analysis of Clinical Dose–Response in a Large Drug Development Portfolio. *Statistics in Biopharmaceutical Research*. 2014;6(4):302-317.
- 37. Mould DR. Model-based meta-analysis: an important tool for making quantitative decisions during drug development. *Clin Pharmacol Ther.* 2012;92(3):283-286.
- 38. Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA. A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. *Clin Pharmacol Ther*. 2011;90(6):828-835.
- 39. Dias S, Ades AE. Absolute or relative effects? Arm-based synthesis of trial data. *Res Synth Methods*. 2016;7(1):23-28.
- 40. White IR, Turner RM, Karahalios A, Salanti G. A comparison of arm-based and contrastbased models for network meta-analysis. *Stat Med.* 2019;38(27):5197-5213.
- 41. Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton N. *NICE DSU Technical* Support Document 18: Methods for population-adjusted indirect comparisons in submission to NICE. 2016.
- 42. Rucker G, Schmitz S, Schwarzer G. Component network meta-analysis compared to a matching method in a disconnected network: A case study. *Biom J.* 2020.

- 43. Pompoli A, Furukawa TA, Efthimiou O, Imai H, Tajika A, Salanti G. Dismantling cognitivebehaviour therapy for panic disorder: a systematic review and component network metaanalysis. *Psychological Medicine*. 2018;48(12):1945-1953.
- 44. Achana FA, Cooper NC, Bujkiewicz S, et al. Network meta-analysis of multiple outcome measures accounting for borrowing of information across outcomes. *BMC Med Res Methodol*. 2014;14.
- 45. Abrams KR, Bujkiewicz S, Dequen P, Jenkins D, Martina R. *GetReal Project No. 115546 WP1: Deliverable 1.5 (Case Study Review: Rheumatoid Arthritis).* 2016.
- 46. Lu G, Ades AE, Sutton AJ, Cooper NJ, Briggs AH, Caldwell DM. Meta-analysis of mixed treatment comparisons at multiple follow-up times. *Stat Med.* 2007;26(20):3681-3699.
- 47. Jansen JP, Vieira MC, Cope S. Network meta-analysis of longitudinal data using fractional polynomials. *Stat Med.* 2015;34(15):2294-2311.
- 48. McCool R, Wilson K, Arber M, et al. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. *Mult Scler Relat Disord*. 2019;29:55-61.
- 49. Soares MO, Dumville JC, Ades AE, Welton NJ. Treatment comparisons for decision making: facing the problems of sparse and few data. *Journal of the Royal Statistical Society Series A*. 2012;177:259-279.
- 50. Dakin HA, Welton NJ, Ades AE, Collins S, Orme M, Kelly S. Mixed treatment comparison of repeated measurements of a continuous endpoint: an example using topical treatments for primary open-angle glaucoma and ocular hypertension. *Stat Med.* 2011;30(20):2511-2535.
- 51. Dutta S., Matsumoto Y., W.F. E. Is it possible to estimate the parameters of the sigmoid E_{max} model with truncated data typical of clinical studies? *Journal of Pharmaceutical Sciences*. 1996;85(2):232-239.